Search Videos by Topic or Participant
Browse by Series:

Multidisciplinary Approach in Muscle-Invasive Bladder Cancer

Insights From: Dean F. Bajorin, MD, MSKCC; Daniel P. Petrylak, MD, Yale;Evan Y. Yu, MD, Seattle Cancer Care
Published: Wednesday, May 13, 2015
For High-Definition, Click
A team-based approach that includes input from a surgeon and medical oncologist is essential for patients with muscle-invasive bladder cancer, Dean F. Bajorin, MD, notes. A multidisciplinary approach in the treatment of muscle-invasive bladder cancer appears to increase the percentage of patients receiving neoadjuvant cisplatin-based chemotherapy, according to study. 

In some situations, patients may not receive treatment due to comorbidities; however, in many situations, neoadjuvant chemotherapy may not be administered simply due to a lack of education on the topic, Evan Y. Yu, MD, mentions. Data from experiences at the Thomas Jefferson University have demonstrated that the multidisciplinary approach results in better outcomes in patients with prostate cancer, moderator Daniel P. Petrylak, MD. This finding is pertinent for the integration of multidisciplinary approaches into evolving managed care and payment models.
Slider Left
Slider Right
For High-Definition, Click
A team-based approach that includes input from a surgeon and medical oncologist is essential for patients with muscle-invasive bladder cancer, Dean F. Bajorin, MD, notes. A multidisciplinary approach in the treatment of muscle-invasive bladder cancer appears to increase the percentage of patients receiving neoadjuvant cisplatin-based chemotherapy, according to study. 

In some situations, patients may not receive treatment due to comorbidities; however, in many situations, neoadjuvant chemotherapy may not be administered simply due to a lack of education on the topic, Evan Y. Yu, MD, mentions. Data from experiences at the Thomas Jefferson University have demonstrated that the multidisciplinary approach results in better outcomes in patients with prostate cancer, moderator Daniel P. Petrylak, MD. This finding is pertinent for the integration of multidisciplinary approaches into evolving managed care and payment models.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x